[Please keep these entries up to date! See the updating procedure at the end of this post. Items that are out of date will be removed.]
NOTE: ANYONE MAY UPDATE THIS FILE
Edits: MRK (Keytrada approved by FDA).
ABBV—HCV program: see ENTA.
ENTA/ABBV—3-DAA HCV regimen: PDUFA date on or about 12/21/14; EMA decision on MAA expected 1H15 (MAA submitted 5/8/14). Next-gen 2-DAA regimen (ABT-493 + ABT-530): ph2 combination in HCV patients starts summer 2014; report ph1 data at unspecified venue in 2014.
ENTA/NVS—EDP-239 + Alisporvir: ph2 DDI in healthy volunteers started Jun 2014; ph2b in combination in HCV patients will start after completion of DDI study.
GILD—Sovaldi + Ledipasvir: PDUDA date 10/10/14; EMA decision expected early 2015 (MAA submitted 2/27/14 and “validated” for review 3/27/14).
GILD—TAF (replacement for Viread in HIV combinations): top-line data from treatment-naïve ph3 4Q14; NDA submission 1Q15.
GILD—Standalone elvitegravir PDUFA date 10/3/14; standalone cobicstat PDUFA date 10/4/14. (In the EU, elvitegravir is approved as Vitekta and cobicstat is approved as Tybost.)